Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
EXCH
Jin Yang Pharmaceutical
★★
Jin Yang Pharmaceutical Lowers CB Conversion Price (5,138→4,668 Won), Increasing Potential Dilution Risk
05/26/2026, 10:51 AM
OWNR
Jin Yang Pharmaceutical
★
Filing of Large Shareholding Report (No Change)
05/18/2026, 03:56 PM
OWNR
Jin Yang Pharmaceutical
★
No change in specific securities ownership by executives and major shareholders
05/18/2026, 03:14 PM
PERI
Jin Yang Pharmaceutical
★
Jinyang Pharmaceutical Q1 2026: Revenue 32.4B, Operating Profit 3.4B; High Debt and CB Dilution Risk
05/15/2026, 11:34 AM